Skip to main content

Advertisement

SpringerLink
Log in

Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

This study evaluated the effect of physiological l-thyroxine (L-T4) treatment on bone metabolism in patients with subclinical hypothyroidism. Sixty-six women with subclinical hypothyroidism (TSH 11.7 ± 0.8 mIU/l) were randomly assigned to receive L-T4 or placebo for 48 weeks. Sixty-one of 66 patients completed the study. Individual L-T4 replacement (mean dosage 85.5 ± 4.3 μg/day) was performed targeting euthyroid thyroid-stimulating hormone (TSH) levels. The primary outcome measure was 24- and 48-week change in markers of bone formation (total and bone alkaline phosphatase [ALP, bone ALP], osteocalcin [OC]) and resorption (pyridinoline [PYD] and deoxypyridinoline [DPD], C-terminal cross-linking telopeptide type I [CTX]). Secondary outcomes were 48-week changes in bone mineral density (BMD) of the lumbar spine and hip, measured by dual-energy X-ray absorptiometry. Compared with placebo, l-thyroxine (n=31) resulted in significant activation of bone turnover. Overall, a significant treatment effect was observed for DPD (between-group difference 16.0%; 95%CI, 10.9 to 21.1), CTX (29.9%; 95%CI, 23.3 to 36.5), and bone ALP (13.2%; 95%CI, 6.6 to 19.7) after 24 weeks. At the end of the study, lumbar BMD in the both treatment groups differed by 1.3% (95%CI, −2.9 to 0.5) with lower levels in l-thyroxine treated women. Significant difference in BMD between groups was also observed at the trochanter. We conclude that physiological l-thyroxine treatment accelerates bone turnover reflecting early activation of bone remodeling units in the initial replacement of subclinical hypothyroidism. The observed bone loss could be interpreted as an adaptive mechanism on decreased bone turnover in preexistent hypothyroidism, and not as l-thyroxine-induced clinically important bone loss. However, long-term studies are needed to confirm this assumption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY (1996) Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81:4278–4289

    CAS  PubMed  Google Scholar 

  2. Eriksen EF (1986) Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 7:379–408

    CAS  PubMed  Google Scholar 

  3. Coindre JM, David JP, Riviere L, Goussot JF, Roger P, de Mascarel A, Meunier PJ (1986) Bone loss in hypothyroidism with hormone replacement: a histomorphometric study. Arch Intern Med 146:48–53

    Article  CAS  PubMed  Google Scholar 

  4. Krolner B, Jorgensen JV, Nielsen SP (1983) Spinal bone mineral content in myxoedema and thyrotoxicosis: effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol (Oxf) 18:439–446

    Google Scholar 

  5. Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT (1988) Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 259:3137–3141

    Article  CAS  PubMed  Google Scholar 

  6. Ribot C, Tremollieres F, Pouilles JM, Louvet JP (1990) Bone mineral density and thyroid hormone therapy. Clin Endocrinol (Oxf) 33:143–153

    Google Scholar 

  7. Greenspan SL, Greenspan FS, Resnick NM, Block JE, Friedlander AL, Genant HK (1991) Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy. Am J Med 91:5–14

    CAS  PubMed  Google Scholar 

  8. Kung AW, Pun KK (1991) Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine. JAMA 265:2688–2691

    Article  CAS  PubMed  Google Scholar 

  9. Campos-Pastor MM, Munoz-Torres M, Escobar-Jimenez F, Ruiz de Almodovar M, Jodar Gimeno E (1993) Bone mass in females with different thyroid disorders: influence of menopausal status. Bone Miner 21:1–8

    CAS  PubMed  Google Scholar 

  10. Garton M, Reid DM, Loveridge N, Robins S, Murchison L, Beckett G, Reid D (1994) Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin Endocrinol (Oxf) 41:747–755

    Google Scholar 

  11. Hanna FW, Pettit RJ, Ammari F, Evans WD, Sandeman D, Lazarus JH (1998) Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol (Oxf) 48:229–234

    Google Scholar 

  12. Grant DJ, McMurdo ME, Mole PA, Paterson CR, Davies RR (1993) Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis. Clin Endocrinol (Oxf) 39:529–533

    Google Scholar 

  13. Duncan WE, Chang A, Solomon B, Wartofsky L (1994) Influence of clinical characteristics and parameters associated with thyroid hormone therapy on the bone mineral density of women treated with thyroid hormone. Thyroid 4:183–190

    CAS  PubMed  Google Scholar 

  14. Franklyn J, Betteridge J, Holder R, Daykin J, Lilley J, Sheppard M (1994) Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol (Oxf) 41:425–432

    Google Scholar 

  15. Schneider DL, Barrett-Connor EL, Morton DJ (1994) Thyroid hormone use and bone mineral density in elderly women: effects of estrogen. JAMA 271:1245–1249

    Article  CAS  Google Scholar 

  16. Hawkins F, Rigopoulou D, Papapietro K, Lopez MB (1994) Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcif Tissue Int 54:16–19

    CAS  PubMed  Google Scholar 

  17. Cooper DS (2001) Clinical practice: subclinical hypothyroidism. N Engl J Med 345:260–265

    Article  CAS  PubMed  Google Scholar 

  18. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G (1988) A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clin Endocrinol (Oxf) 29:63–75

    Google Scholar 

  19. Ross DS (1993) Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. Am J Med 95:385–388

    CAS  PubMed  Google Scholar 

  20. Jaeschke R, Guyatt G, Gerstein H, Patterson C, Molloy W, Cook D, Harper S, Griffith L, Carbotte R (1996) Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 11:744–749

    Google Scholar 

  21. Pines A, Dotan I, Tabori U, Villa Y, Mijatovic V, Levo Y, Ayalon D (1999) L-thyroxine prevents the bone-conserving effect of HRT in postmenopausal women with subclinical hypothyroidism. Gynecol Endocrinol 13:196–201

    Google Scholar 

  22. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B (2001) TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 86:4860–4866

    CAS  PubMed  Google Scholar 

  23. Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694–702

    CAS  PubMed  Google Scholar 

  24. Gluer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK (1995) Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 5:262–270

    CAS  PubMed  Google Scholar 

  25. Ross DS (1991) Monitoring L-thyroxine therapy: lessons from the effects of L-thyroxine on bone density. Am J Med 91:1–4

    CAS  PubMed  Google Scholar 

  26. Bergmann P, Dediste A, Demeester-Mirkine N, Deconinck I, Corvilain J (1989) Serum bone Gla protein (BGP) in primary hypothyroidism before and during treatment with thyroid hormones. Horm Metab Res 21:47–48

    CAS  PubMed  Google Scholar 

  27. Gam AN, Jensen GF, Hasselstrom K, Olsen M, Nielsen KS (1991) Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH. J Endocrinol Invest 14:451–455

    CAS  PubMed  Google Scholar 

  28. Campbell J, Day P, Diamond T (1996) Fine adjustments in thyroxine replacement and its effect on bone metabolism. Thyroid 6:75–78

    CAS  PubMed  Google Scholar 

  29. Woitge HW, Seibel MJ, Ziegler R (1996) Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases. Clin Chem 42:1796–1804

    CAS  PubMed  Google Scholar 

  30. Sheppard MC, Holder R, Franklyn JA (2002) Levothyroxine treatment and occurrence of fracture of the hip. Arch Intern Med 162:338–343

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Medicine, University Hospitals, CH-4031, Basel, Switzerland

    Christian Meier, Müller Beat, Merih Guglielmetti, Mirjam Christ-Crain, Jean-Jacques Staub & Marius Kraenzlin

  2. Bone Research Laboratory, ANZAC Research Institute, University of Sydney, NSW 2139, Concord, Australia

    Christian Meier

Authors
  1. Christian Meier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Müller Beat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Merih Guglielmetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mirjam Christ-Crain
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-Jacques Staub
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marius Kraenzlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Meier.

Additional information

This work was supported by grants from the Swiss National Science Foundation (32.27866.89, 32.37792.93, and 32.37792.98) and unconditional research grants from Henning Berlin, Sandoz Research, and Roche Research foundations. Presented in part at the 24th annual meeting of the American Society for Bone and Mineral Research, San Antonio, 2002, and at the 84th annual meeting of The Endocrine Society, San Francisco, 2002.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meier, C., Beat, M., Guglielmetti, M. et al. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int 15, 209–216 (2004). https://doi.org/10.1007/s00198-003-1527-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-003-1527-8

Keywords

Search

Navigation